Pharmaceutical Synthesis Processes Utilizing Phase-Transfer Catalyst Systems are a critical class of chemical methodologies employed in the large-scale production of active pharmaceutical ingredients and their key intermediates. Identified by CAS: {cas_number}, these processes leverage advanced catalyst systems to improve reaction efficiency across biphasic organic-aqueous boundaries, leading to enhanced yields and selectivity. The representative molecular formula is {molecular_formula}, complemented by a molecular weight of {molecular_weight}. For unequivocal identification, the process utilizes compounds bearing the IUPAC name {iupac_name}, and the unique InChIKey {inchikey} is recognized within the chemical information community. Typically, such catalyst systems are employed as essential reagents or process aids in the pharmaceutical sector, not as APIs or excipients themselves.
A discussion of the relevant physical and chemical characteristics helps define the optimal handling and process design for these catalyst systems. The boiling point and melting point, if measurable, serve as primary determinants for safe handling and storage. Parameters like density, flash point, and vapor pressure further aid in engineering assessments and risk management. For instance, if a given phase-transfer catalyst exhibits a flash point within the common industrial range, this data underscores the importance of proper flammability precautions. Each of these values is meticulously established through validated testing, serving as a benchmark for both quality control and compliance with regulatory standards.
Regulatory oversight is a cornerstone of the commercial supply of such catalyst systems. European regulatory obligations are met via REACH, with registration information, relevant article numbers, and applicable tonnage bands dictating market access within the EU. U.S. regulatory status is confirmed under the TSCA inventory, referencing the appropriate section to demonstrate lawful commercialization. When used in pharmaceutical manufacturing, applicable ICH guidelines, such as ICH Q3C(R8) for residual solvents or ICH Q7(R1) for good manufacturing practice, designate acceptable exposure limits and quality thresholds. Global regulatory harmonization is further reflected in GHS hazard classification, which details all corresponding hazard and precautionary statements as well as the required signal word. Pharmacopeial referencings, including chapter numbers where available, support compendial compliance for customers seeking full regulatory alignment. In workplace settings, occupational exposure values such as the OSHA Permissible Exposure Limit and the NIOSH Recommended Exposure Limit foster a culture of industrial hygiene and employee protection.
Within the pharmaceutical industry, phase-transfer catalyst systems are most commonly applied in synthetic transformations where traditional homogeneous catalysis is suboptimal, especially in constructing critical intermediates for a range of drug molecules. These catalysts are instrumental in processes such as alkylation, esterification, and nucleophilic substitution, often enabling reactions to proceed under milder conditions with improved selectivity. This unlocks advantages in the production of key medications and supports the scalable manufacture of high-value therapeutic agents. While the catalysts themselves are not administered as therapies, their role is fundamental in the reliable synthesis of numerous pharmaceuticals.
Packaging of phase-transfer catalyst systems follows established industry norms, with standard offerings including 25-kilogram drums, 200-kilogram drums, and intermediate bulk containers for larger-scale applications. Storage guidance is informed by GHS stability data, and these systems are customarily kept tightly sealed in cool, dry, well-ventilated conditions away from incompatible materials. As a general rule within this chemical class, an industry-standard shelf life guidance of two years from date of manufacture is advisable, provided proper storage conditions are observed.
References for further information include PubChem, where a compound summary may be accessed at https://pubchem.ncbi.nlm.nih.gov/compound/{cid}, the NIST Chemistry WebBook at https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}, the European Chemicals Agency (ECHA) at {echa_url}, and the EPA TSCA Inventory at https://www.epa.gov/tsca-inventory. These sources enable chemical professionals to explore substance-specific data, regulatory filings, and technical support documents relevant to the synthesis and application of phase-transfer catalyst systems in pharmaceutical manufacturing.
Related Articles
